Cell therapy firm ProKidney's Q3 net loss narrows

Prokidney

10/11/2025 21:33

Overview

ProKidney ended Q3 2025 with $272 mln in cash, supporting operations into mid-2027

Outlook

Company expects cash to support operations into mid-2027

Result Drivers

R&D EXPENSES - Decrease in R&D expenses due to winding down of completed or terminated trials

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Operating Expenses
$38.76 mln
Q3 Operating Income
-$38.54 mln
Q3 Pretax Profit
-$35.28 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 3 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Prokidney Corp is $6.50, about 55.5% above its November 7 closing price of $2.89

Press Release: ID:nGNX820zl0

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)